JPRN-C000000375已完成未知
A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children. - A combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with nephrotic syndrome and diffuse mesangial proliferation in children.
The Japanese Pediatric IgA Nephropathy of Treatment Study Group0 个研究点目标入组 20 人开始时间: 2006年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2years-old 至 18years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Other renal or systemic forms of nephrotic syndrome defined on renal biopsy, clinical features or serology (Henoch-Schönlein nephritis, systemic lupus erythematosus). 2.Medical history of allergy or hypersensitivity reactions to prednisolone, mizorobine, warfarin or dipyridamole 3.Chronic renal dysfunction 4.Active infectious disease 5.Severe liver disfunction 6.History of corticosteroid and immunosupression administration 7.Pregnancy 8.Judged inappropriate for this study by the physicians
研究者
相似试验
已完成
不适用
A combination of prednisolone and mizoribine and a combination of prednisolone, mizoribine, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial prolideration in children:A randomized controlled trial of efficacy and safetyIgA nephropathy in childrenJPRN-C000000363The Japanese Pediatric IgA Nephropathy of Treatment Study Group80
已完成
不适用
A combination of prednisolone, warfarin and dipyridamole for IgA nephropathy with diffuse mesangial proliferation in children.IgA nephropathy in childrenJPRN-C000000374The Japanese Pediatric IgA Nephropathy of Treatment Study Group20
未知
不适用
A combination of cyclosporine and prednisolone and a combination of methylprednisolone, cyclosporine and prednisolone for steroid-resistant nephrotic syndrome in children: A randomized controlled studySteroid-resistant nephrotic syndrome in childrenJPRN-C000000007Japanese Study Group of Kidney Disease in Children90
进行中（未招募）
3 期
PSL/CYA therapy for early onset of VKH diseaseVogt-Koyanagi-Harada diseaseJPRN-jRCTs011180031amba Kenichi120
进行中（未招募）
不适用
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Elderly Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial'Diffuse Large-Bcell LymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001100-40-ITCELL THERAPEUTICS INC. SEDE SECONDARIA280